Inhaled CBD reduced two key neuroinflammation pathways in Alzheimer's disease mice
CBD inhalation significantly reduced expression of IDO and cGAS, two immune regulators implicated in Alzheimer's neuroinflammation, along with decreasing proinflammatory cytokines in a transgenic mouse model.
Quick Facts
What This Study Found
CBD treatment reduced both IDO and cGAS expression in the brains of 5XFAD Alzheimer's mice, with corresponding decreases in TNF-alpha, IL-1beta, and IFN-gamma. Bioinformatics identified AKT1, TRPV1, and GPR55 as potential molecular targets.
Key Numbers
CBD significantly reduced IDO and cGAS expression. Proinflammatory cytokines TNF-alpha, IL-1beta, and IFN-gamma all decreased. Three molecular targets identified: AKT1 (cell survival signaling), TRPV1 (neuroinflammation), GPR55 (immune cell activation).
How They Did This
5XFAD transgenic Alzheimer's mouse model treated with inhaled CBD. Outcomes measured by flow cytometry, immunofluorescence, gene expression analysis, and STRING-based bioinformatics for target identification.
Why This Research Matters
Alzheimer's research has increasingly recognized neuroinflammation as a driver of disease progression beyond amyloid plaques. Identifying that CBD simultaneously targets two distinct inflammatory pathways offers a mechanistic basis for further investigation.
The Bigger Picture
Most Alzheimer's drugs have targeted amyloid or tau. The growing recognition that immune dysfunction contributes to neuronal damage opens new therapeutic avenues, and CBD's multi-target anti-inflammatory profile makes it an interesting candidate.
What This Study Doesn't Tell Us
Mouse model only, using a transgenic strain that overexpresses Alzheimer's mutations not typical of most human cases. Inhaled CBD dosing in mice may not translate to human administration. Bioinformatics predictions of molecular targets need experimental validation.
Questions This Raises
- ?Would CBD show similar effects in other Alzheimer's models?
- ?Can these inflammatory biomarkers serve as treatment response markers in human trials?
Trust & Context
- Key Stat:
- CBD simultaneously reduced two distinct neuroinflammation pathways
- Evidence Grade:
- Transgenic mouse study with multiple analytical methods provides mechanistic insight, but uses an aggressive Alzheimer's model and has not been replicated in humans.
- Study Age:
- Published in 2025.
- Original Title:
- Rethinking Alzheimer's: Harnessing Cannabidiol to Modulate IDO and cGAS Pathways for Neuroinflammation Control.
- Published In:
- eNeuro, 12(10) (2025)
- Authors:
- Emami Naeini, Sahar, Bhandari, Bidhan(3), Hill, Breanna(2), Perez-Morales, Nayeli, Rogers, Hannah M, Khodadadi, Hesam, Young, Nancy, Maciel, Lívia Maria, Yu, Jack C, Hess, David C, Morgan, John C, Lopes Salles, Évila, Wang, Lei P, Baban, Babak
- Database ID:
- RTHC-06403
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
Could CBD help with Alzheimer's disease?
This mouse study found CBD reduced two key inflammation pathways in the brain associated with Alzheimer's progression. However, these are very early findings in an animal model, far from proving benefit in humans.
How does CBD reduce brain inflammation in this study?
CBD appeared to work through multiple targets, reducing IDO and cGAS pathways and lowering inflammatory molecules like TNF-alpha. The researchers identified AKT1, TRPV1, and GPR55 as likely molecular targets.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-06403APA
Emami Naeini, Sahar; Bhandari, Bidhan; Hill, Breanna; Perez-Morales, Nayeli; Rogers, Hannah M; Khodadadi, Hesam; Young, Nancy; Maciel, Lívia Maria; Yu, Jack C; Hess, David C; Morgan, John C; Lopes Salles, Évila; Wang, Lei P; Baban, Babak. (2025). Rethinking Alzheimer's: Harnessing Cannabidiol to Modulate IDO and cGAS Pathways for Neuroinflammation Control.. eNeuro, 12(10). https://doi.org/10.1523/ENEURO.0114-25.2025
MLA
Emami Naeini, Sahar, et al. "Rethinking Alzheimer's: Harnessing Cannabidiol to Modulate IDO and cGAS Pathways for Neuroinflammation Control.." eNeuro, 2025. https://doi.org/10.1523/ENEURO.0114-25.2025
RethinkTHC
RethinkTHC Research Database. "Rethinking Alzheimer's: Harnessing Cannabidiol to Modulate I..." RTHC-06403. Retrieved from https://rethinkthc.com/research/emami-2025-rethinking-alzheimers-harnessing-cannabidiol
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.